Manufacturing of Components Using Rapid Prototyping Technology

Bakalářská práce je zaměřena na návrh planetové převodovky vymodelované v 3D programu Autodesk Inventor, a její zhotovení pomocí aditivní technologie Rapid Prototyping s rozšířenou metodou Fused Deposition Modelling. Ze začátku bakalářské práce jsou představeny nejrozšířenější metody Rapid Prototyping, dále zahrnuje postup při návrhu planetové převodky, postup modelování v 3D programu, a rozbor potřebných nastavení pro 3D tiskárnu.The aim of the bachelor thesis is design of planetary gear modeled in 3D program Autodesk Invertor and made using additive technology extended by Fused Deposit Modelling. In the first section is presented the most widely used methods of Rapid Prototyping. The next section is focused on design of planet gear, the process of modeling in 3D software, and analysis of needed configurations for the 3D printer.

Design of axis of milling machine

Tato diplomová práce se zabývá návrhem rámu a pracovních os stolní frézky. Teoretická část je pojata formou rešerše v oblasti konstrukce malých obráběcích strojů. Praktickou částí je poté provedení návrhu pracovních os a návrhu rámové konstrukce. Do praktické části bude také zahrnut výběr hlavních důležitých komponentů.This master thesis is dealing with the design of the frame and working axis of the desktop milling machine. The theoretical part is in the form of a research of the construction of small machine tools. Practical part concerns the idea for a design of the working axis, as well as the design of the frame construction. Practical part also contains the selection of the main and most important components.

Prijetnje međusobnom povjerenju: češki lokalni političari i lokalni novinari u doba profesionalne političke komunikacije

The study discusses changes in the relationship between local journalists and local politicians in the Czech Republic as a consequence of the professionalization of political communications at national as well as local levels following the so-called Velvet Revolution of 1989. This phenomenon has been studied widely in Western democracies but is relatively new in the Czech Republic. Politicians’ improved communication skills and the employment of communication professionals in politics influence trust – a key component in the relationship – between politicians and journalists. The article is based on semi-structured interviews with 10 journalists and 11 politicians from different Czech localities, which aim to explore how these actors understand and maintain levels of mutual trust. First we describe key components of trust and explain why in the era of professionalized political communication trust is perceived as more threatened than in the 1990s and we conclude by exploring the three most important threats to trust as identified by our interviewees.Studija se bavi promjenama u odnosu između lokalnih novinara i lokalnih političara u Češkoj kao posljedicom profesionalizacije političke komunikacije, kako na nacionalnoj tako i na lokalnoj razini, nakon takozvane Baršunaste revolucije iz 1989. godine. Taj je fenomen već istraživan u zapadnim demokracijama, a u Češkoj je relativno nov. Unaprijeđene komunikacijske vještine političara te zapošljavanje komunikacijskih stručnjaka u politici utječu na povjerenje – temeljnu komponentu u odnosu političara i novinara. Članak se temelji na saznanjima iz polustrukturiranih intervjua s 10 novinara i 11 političara iz različitih mjesta u Češkoj, kojima je cilj istražiti na koji način oni shvaćaju i održavaju razine međusobnog povjerenja. Najprije smo opisali ključne komponente povjerenja te objasnili zašto se povjerenje smatra ugroženijim u doba rofesionalizirane političke komunikacije nego što je bilo tijekom 1990-ih. Naposljetku zaključujemo članak istraživanjem triju najvažnijih prijetnji povjerenju koje su identificirali naši ispitanici

Monitoring media pluralism in Europe : application of the Media Pluralism Monitor 2017 in the European Union, FYROM, Serbia & Turkey : country report : Czech Republic

This report was co-funded by the European Commissio

Prijetnje međusobnom povjerenju: češki lokalni političari i lokalni novinari u doba profesionalne političke komunikacije

The study discusses changes in the relationship between local journalists and local politicians in the Czech Republic as a consequence of the professionalization of political communications at national as well as local levels following the so-called Velvet Revolution of 1989. This phenomenon has been studied widely in Western democracies but is relatively new in the Czech Republic. Politicians’ improved communication skills and the employment of communication professionals in politics influence trust – a key component in the relationship – between politicians and journalists. The article is based on semi-structured interviews with 10 journalists and 11 politicians from different Czech localities, which aim to explore how these actors understand and maintain levels of mutual trust. First we describe key components of trust and explain why in the era of professionalized political communication trust is perceived as more threatened than in the 1990s and we conclude by exploring the three most important threats to trust as identified by our interviewees.Studija se bavi promjenama u odnosu između lokalnih novinara i lokalnih političara u Češkoj kao posljedicom profesionalizacije političke komunikacije, kako na nacionalnoj tako i na lokalnoj razini, nakon takozvane Baršunaste revolucije iz 1989. godine. Taj je fenomen već istraživan u zapadnim demokracijama, a u Češkoj je relativno nov. Unaprijeđene komunikacijske vještine političara te zapošljavanje komunikacijskih stručnjaka u politici utječu na povjerenje – temeljnu komponentu u odnosu političara i novinara. Članak se temelji na saznanjima iz polustrukturiranih intervjua s 10 novinara i 11 političara iz različitih mjesta u Češkoj, kojima je cilj istražiti na koji način oni shvaćaju i održavaju razine međusobnog povjerenja. Najprije smo opisali ključne komponente povjerenja te objasnili zašto se povjerenje smatra ugroženijim u doba rofesionalizirane političke komunikacije nego što je bilo tijekom 1990-ih. Naposljetku zaključujemo članak istraživanjem triju najvažnijih prijetnji povjerenju koje su identificirali naši ispitanici

Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma:Analyses From Longer Follow-up of the OCEAN and HORIZON Studies

Introduction: Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS) but directionally different overall survival (OS) favoring pomalidomide (hazard ratio [HR], 1.10) in OCEAN. Methods: These analyses further investigated prognostic subgroups impacting survival in updated data from the randomized, phase 3 OCEAN study (NCT03151811; date: February 3, 2022) and the phase 2 HORIZON study (NCT02963493; date: February 2, 2022). Results: In OCEAN, subgroups prognostic for OS were age (P = .011; &lt;65 years favored pomalidomide) and no previous autologous stem cell transplant (ASCT) or progression &gt;36 months after ASCT (P = .001; favored melflufen). Overall, 245 of 495 (49%) patients randomized had received a previous ASCT, of which 202 (82%) had progressed within 36 months following their ASCT. When excluding patients who had progressed &lt;36 months post-ASCT (melflufen group, n = 145; pomalidomide group, n = 148), median OS was 23.6 months with melflufen and 19.8 months with pomalidomide (HR, 0.83 [95% CI, 0.62-1.12]; P = .22). Among patients with triple-class refractory disease in HORIZON, patients who had progressed &lt;36 months post-ASCT (n = 58) had a lower response rate and shorter duration of response and PFS than the remaining patients (n = 52). Safety was consistent with previous reports. Conclusion: These analyses demonstrate a consistent benefit for melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma who have not received an ASCT or progressed &gt;36 months after receiving an ASCT (ClinicalTrials.gov identifier: NCT03151811).</p

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.

OBJECTIVES AND DESIGN: A novel risk stratification algorithm estimating risk of death in patients with relapsed multiple myeloma starting second-line treatment was recently developed using multivariable Cox regression of data from a Czech registry. It uses 16 parameters routinely collected in medical practice to stratify patients into four distinct risk groups in terms of survival expectation. To provide insight into generalisability of the risk stratification algorithm, the study aimed to validate the risk stratification algorithm using real-world data from specifically designed retrospective chart audits from three European countries. PARTICIPANTS AND SETTING: Physicians collected data from 998 patients (France, 386; Germany, 344; UK, 268) and applied the risk stratification algorithm. METHODS: The performance of the Cox regression model for predicting risk of death was assessed by Nagelkerke's R2, goodness of fit and the C-index. The risk stratification algorithm's ability to discriminate overall survival across four risk groups was evaluated using Kaplan-Meier curves and HRs. RESULTS: Consistent with the Czech registry, the stratification performance of the risk stratification algorithm demonstrated clear differentiation in risk of death between the four groups. As risk groups increased, risk of death doubled. The C-index was 0.715 (95% CI 0.690 to 0.734). CONCLUSIONS: Validation of the novel risk stratification algorithm in an independent 'real-world' dataset demonstrated that it stratifies patients in four subgroups according to survival expectation

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Background Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1: 1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1.3 mg/m(2); intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat population. All participants who received at least one dose of study drug were included in the safety analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary endpoint are presented. Findings Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib group; 465 to the bortezomib group). Median follow-up was 11.9 months (IQR 9.3-16.1) in the carfilzomib group and 11.1 months (8.2-14.3) in the bortezomib group. Median progression-free survival was 18.7 months (95% CI 15.6-not estimable) in the carfilzomib group versus 9.4 months (8.4-10.4) in the bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0.53 [95% CI 0.44-0.65]; p<0.0001). On-study death due to adverse events occurred in 18 (4%) of 464 patients in the carfilzomib group and in 16 (3%) of 465 patients in the bortezomib group. Serious adverse events were reported in 224 (48%) of 463 patients in the carfilzomib group and in 162 (36%) of 456 patients in the bortezomib group. The most frequent grade 3 or higher adverse events were anaemia (67 [14%] of 463 patients in the carfilzomib group vs 45 [10%] of 456 patients in the bortezomib group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia (39 [8%] vs 43 [9%]), and pneumonia (32 [7%] vs 36 [8%]). Interpretation For patients with relapsed or refractory multiple myeloma, carfilzomib with dexamethasone could be considered in cases in which bortezomib with dexamethasone is a potential treatment option